Angiogenesis as a therapeutic target in arthritis in 2011: Learning the lessons of the colorectal cancer experience

Angiogenesis

Volumn 14, Issue 3, 2011, Pages 223-234

  Thairu, Ngayu ^a   Kiriakidis, Serafim ^a   Dawson, Peter ^a   Paleolog, Ewa ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Angiogenesis; Colorectal cancer; Rheumatoid arthritis; VEGF

Indexed keywords

2 BENZOYLPHENOXY ACETAMIDE; 2 OG; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; ANTINEOPLASTIC AGENT; BENZOPHENONE DERIVATIVE; BEVACIZUMAB; CETUXIMAB; ERLOTINIB; ERYTHROPOIETIN; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FLUOROURACIL; FOLINIC ACID; HYPOXIA INDUCIBLE FACTOR; LAPATINIB; OXALIPLATIN; PANITUMUMAB; PLATELET DERIVED GROWTH FACTOR B; ROMIDEPSIN; TIE 1 RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 1 ANTIBODY;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTHRITIS; BREAST CANCER; CANCER SURVIVAL; COLLAGEN INDUCED ARTHRITIS; COLORECTAL CANCER; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DRUG EFFICACY; HUMAN; HYPERTENSION; HYPOXIA; LUNG NON SMALL CELL CANCER; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN TARGETING; PROTEINURIA; REVIEW; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SOLID TUMOR; SYNOVIUM; THROMBOEMBOLISM;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; COLORECTAL NEOPLASMS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 80052775143     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-011-9208-2     Document Type: Review

References (145)

1. DR Senger SJ Galli AM Dvorak CA Perruzzi VS Harvey HF Dvorak 1983 Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid Science 219 983 985 6823562 1:STN:280:DyaL3s7hvF2mtw%3D%3D
2. DR Senger CA Perruzzi J Feder HF Dvorak 1986 A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines Cancer Res 46 5629 5632 3756910 1:CAS:528:DyaL2sXhtlGrsw%3D%3D (Pubitemid 17177959)
3. EM Barrett DG Scott NJ Wiles DP Symmons 2000 The impact of rheumatoid arthritis on employment status in the early years of disease: a UK community-based study Rheumatology (Oxford) 39 1403 1409 1:STN:280: DC%2BD3M7gtFaitA%3D%3D (Pubitemid 32045868)
4. T Sokka H Kautiainen T Pincus SM Verstappen A Aggarwal R Alten D Andersone H Badsha E Baecklund M Belmonte J Craig-Muller LM da Mota A Dimic NA Fathi G Ferraccioli W Fukuda P Geher F Gogus N Hajjaj-Hassouni H Hamoud G Haugeberg D Henrohn K Horslev-Petersen R Ionescu D Karateew R Kuuse IM Laurindo J Lazovskis R Luukkainen A Mofti E Murphy A Nakajima O Oyoo SC Pandya C Pohl D Predeteanu M Rexhepi S Rexhepi B Sharma E Shono J Sibilia S Sierakowski FN Skopouli S Stropuviene S Toloza I Valter A Woolf H Yamanaka 2010 Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA Study Arthritis Res Ther 12 R42 20226018
5. Z Szekanecz L Gaspar AE Koch 2005 Angiogenesis in rheumatoid arthritis Front Biosci 10 1739 1753 15769663 1:CAS:528:DC%2BD2MXisVers7o%3D (Pubitemid 40529034)
6. Z Szekanecz AE Koch 2008 Targeting Angiogenesis in Rheumatoid Arthritis Curr Rheumatol Rev 4 298 303 20706557 1:CAS:528:DC%2BD1cXhtlOnt7zM
7. Z Szekanecz G Szegedi AE Koch 1998 Angiogenesis in rheumatoid arthritis: pathogenic and clinical significance J Investig Med 46 27 41 9549225 1:STN:280:DyaK1c3htVeqsw%3D%3D (Pubitemid 128452767)
8. EM Paleolog 2009 The vasculature in rheumatoid arthritis: cause or consequence? Int J Exp Pathol 90 249 261 19563609 1:CAS:528:DC%2BD1MXotV2ju7Y%3D
9. RA Brown JB Weiss IW Tomlinson P Phillips S Kumar 1980 Angiogenic factor from synovial fluid resembling that from tumours Lancet 1 682 685 6103093 1:STN:280:DyaL3c7os1Ghtw%3D%3D (Pubitemid 10131683)
10. EL Semble RA Turner EL McCrickard 1985 Rheumatoid arthritis and osteoarthritis synovial fluid effects on primary human endothelial cell cultures J Rheumatol 12 237 241 3897531 1:STN:280:DyaL2M3pt12juw%3D%3D (Pubitemid 15025361)
11. P Kumar A Erroi A Sattar S Kumar 1985 Weibel-Palade bodies as a marker for neovascularization induced by tumor and rheumatoid angiogenesis factors Cancer Res 45 4339 4348 2411400 1:STN:280:DyaL2M3ot1eiuw%3D%3D (Pubitemid 16224895)
12. U Fearon K Griosios A Fraser R Reece P Emery PF Jones DJ Veale 2003 Angiopoietins, growth factors, and vascular morphology in early arthritis J Rheumatol 30 260 268 12563678 1:CAS:528:DC%2BD3sXhslWntLg%3D (Pubitemid 36152587)
13. A Ceponis YT Konttinen S Imai M Tamulaitiene TF Li JW Xu J Hietanen S Santavirta HG Fassbender 1998 Synovial lining, endothelial and inflammatory mononuclear cell proliferation in synovial membranes in psoriatic and reactive arthritis: a comparative quantitative morphometric study Br J Rheumatol 37 170 178 9569072 1:STN:280:DyaK1c3ivVShtQ%3D%3D
14. DA Walsh M Wade PI Mapp DR Blake 1998 Focally regulated endothelial proliferation and cell death in human synovium Am J Pathol 152 691 702 9502411 1:STN:280:DyaK1c7mtFGitA%3D%3D (Pubitemid 28110716)
15. E Izquierdo JD Canete R Celis B Santiago A Usategui R Sanmarti MJ Del Rey JL Pablos 2009 Immature blood vessels in rheumatoid synovium are selectively depleted in response to anti-TNF therapy PLoS One 4 e8131 19956574
16. MJ Larche M Seymour A Lim RJ Eckersley F Petavy F Chiesa I Rioja PT Lukey M Binks C McClinton K Dolan PC Taylor 2010 Quantitative power doppler ultrasonography is a sensitive measure of metacarpophalangeal joint synovial vascularity in rheumatoid arthritis and declines significantly following a 2-week course of oral low-dose corticosteroids J Rheumatol 37 2493 2501 20889600 1:CAS:528:DC%2BC3MXmvVamtg%3D%3D
17. PC Taylor A Steuer J Gruber DO Cosgrove MJ Blomley PA Marsters CL Wagner C McClinton RN Maini 2004 Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis Arthritis Rheum 50 1107 1116 15077292 1:STN:280:DC%2BD2c7otVGqtg%3D%3D (Pubitemid 38480820)
18. N Ferrara HP Gerber J LeCouter 2003 The biology of VEGF and its receptors Nat Med 9 669 676 12778165 1:CAS:528:DC%2BD3sXktFOnur4%3D (Pubitemid 36749215)
19. N Ferrara 2004 Vascular endothelial growth factor: basic science and clinical progress Endocr Rev 25 581 611 15294883 1:CAS:528:DC%2BD2cXns1Ght74%3D (Pubitemid 39099316)
20. QT Ho CJ Kuo 2007 Vascular endothelial growth factor: biology and therapeutic applications Int J Biochem Cell Biol 39 1349 1357 17537667 1:CAS:528:DC%2BD2sXnslWltLs%3D (Pubitemid 47031045)
21. N Ferrara 2009 VEGF-A: a critical regulator of blood vessel growth Eur Cytokine Netw 20 158 163 20167554 1:CAS:528:DC%2BC3cXns1Ol
22. AE Koch LA Harlow GK Haines EP Amento EN Unemori WL Wong RM Pope N Ferrara 1994 Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis J Immunol 152 4149 4156 7511670 1:CAS:528:DyaK2cXjt1Sltbk%3D (Pubitemid 24111088)
23. RA Fava NJ Olsen G Spencer-Green KT Yeo TK Yeo B Berse RW Jackman DR Senger HF Dvorak LF Brown 1994 Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue J Exp Med 180 341 346 8006592 1:CAS:528: DyaK2cXktlejsL4%3D (Pubitemid 24181082)
24. K Kikuchi M Kubo T Kadono N Yazawa H Ihn K Tamaki 1998 Serum concentrations of vascular endothelial growth factor in collagen diseases Br J Dermatol 139 1049 1051 9990370 1:STN:280:DyaK1M7ksVWrsw%3D%3D (Pubitemid 29010544)
25. EM Paleolog S Young AC Stark RV McCloskey M Feldmann RN Maini 1998 Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis Arthritis Rheum 41 1258 1265 9663484 1:CAS:528:DyaK1cXkslWjtLs%3D (Pubitemid 28313429)
26. M Ikeda Y Hosoda S Hirose Y Okada E Ikeda 2000 Expression of vascular endothelial growth factor isoforms and their receptors Flt-1, KDR, and neuropilin-1 in synovial tissues of rheumatoid arthritis J Pathol 191 426 433 10918218 1:CAS:528:DC%2BD3cXlvFCrsL0%3D (Pubitemid 30649912)
27. E Brouwer AS Gouw MD Posthumus MA van Leeuwen AL Boerboom J Bijzet R Bos PC Limburg CG Kallenberg J Westra 2009 Hypoxia inducible factor-1-alpha (HIF-1alpha) is related to both angiogenesis and inflammation in rheumatoid arthritis Clin Exp Rheumatol 27 945 951 20149310 1:STN:280: DC%2BC3c7gtlSjsA%3D%3D
28. SS Lee YS Joo WU Kim DJ Min JK Min SH Park CS Cho HY Kim 2001 Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis Clin Exp Rheumatol 19 321 324 11407088 1:STN:280:DC%2BD3MzksVaquw%3D%3D
29. A Giatromanolaki E Sivridis N Athanassou E Zois PE Thorpe RA Brekken KC Gatter AL Harris IM Koukourakis MI Koukourakis 2001 The angiogenic pathway "vascular endothelial growth factor/flk-1(KDR)-receptor" in rheumatoid arthritis and osteoarthritis J Pathol 194 101 108 11329148 1:CAS:528: DC%2BD3MXjvVahtbY%3D
30. T Pufe W Petersen B Tillmann R Mentlein 2001 Splice variants VEGF121 and VEGF165 of the angiogenic peptide vascular endothelial cell growth factor are expressed in the synovial tissue of patients with rheumatoid arthritis J Rheumatol 28 1482 1485 11469450 1:CAS:528:DC%2BD3MXlsVymsrs%3D (Pubitemid 32660616)
31. H Sone M Sakauchi A Takahashi H Suzuki N Inoue K Iida H Shimano H Toyoshima Y Kawakami Y Okuda K Matsuo N Yamada 2001 Elevated levels of vascular endothelial growth factor in the sera of patients with rheumatoid arthritis correlation with disease activity Life Sci 69 1861 1869 11693266 1:CAS:528:DC%2BD3MXmvV2htrs%3D (Pubitemid 32835268)
32. A Kuryliszyn-Moskal PA Klimiuk S Sierakowski M Ciolkiewicz 2006 A study on vascular endothelial growth factor and endothelin-1 in patients with extra-articular involvement of rheumatoid arthritis Clin Rheumatol 25 314 319 16247585
33. D Kurosaka K Hirai M Nishioka Y Miyamoto K Yoshida K Noda T Ukichi M Yanagimachi K Furuya E Takahashi I Kingetsu K Fukuda A Yamada 2010 Clinical significance of serum levels of vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in patients with rheumatoid arthritis J Rheumatol 37 1121 1128 20436077 1:CAS:528:DC%2BC3cXptlamsro%3D
34. SC Ballara PC Taylor P Reusch D Marmé M Feldmann RN Maini EM Paleolog 2001 Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis Arthritis Rheum 44 2055 2064 11592367 1:CAS:528:DC%2BD3MXpt12ltro%3D (Pubitemid 33644048)
35. D Kurosaka K Hirai M Nishioka Y Miyamoto K Yoshida E Takahashi T Ukichi K Noda M Yanagimachi K Furuya K Fukuda A Yamada 2009 Correlation between synovial blood flow signals and serum vascular endothelial growth factor levels in patients with refractory rheumatoid arthritis Mod Rheumatol 19 187 191 19219643 1:CAS:528:DC%2BD1MXjvFaqtLw%3D
36. RO Williams E Paleolog M Feldmann 2007 Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases Curr Opin Pharmacol 7 412 417 17627887 1:CAS:528:DC%2BD2sXpsFKqs7o%3D (Pubitemid 47289266)
37. J Lu T Kasama K Kobayashi Y Yoda F Shiozawa M Hanyuda M Negishi H Ide M Adachi 2000 Vascular endothelial growth factor expression and regulation of murine collagen-induced arthritis J Immunol 164 5922 5927 10820274 1:CAS:528:DC%2BD3cXjslemtLc%3D (Pubitemid 30389839)
38. S Thornton D Sowders B Aronow DP Witte HI Brunner EH Giannini R Hirsch 2002 DNA microarray analysis reveals novel gene expression profiles in collagen-induced arthritis Clin Immunol 105 155 168 12482389 1:CAS:528:DC%2BD38XpsF2qsr4%3D (Pubitemid 35471663)
39. LM Hermann M Pinkerton K Jennings L Yang A Grom D Sowders S Kersten DP Witte R Hirsch S Thornton 2005 Angiopoietin-like-4 is a potential angiogenic mediator in arthritis Clin Immunol 115 93 101 15870027 1:CAS:528: DC%2BD2MXkslyqu78%3D (Pubitemid 40616175)
40. M de Bandt M Grossin AJ Weber M Chopin C Elbim M Pla MA Gougerot-Pocidalo M Gaudry 2000 Suppression of arthritis and protection from bone destruction by treatment with TNP-470/AGM-1470 in a transgenic mouse model of rheumatoid arthritis Arthritis Rheum 43 2056 2063 11014357
41. AL Arsenault S Lhotak WL Hunter ML Banquerigo E Brahn 1998 Taxol involution of collagen-induced arthritis: ultrastructural correlation with the inhibition of synovitis and neovascularization Clin Immunol Immunopathol 86 280 289 9557161 1:CAS:528:DyaK1cXis1Oitb0%3D (Pubitemid 28169459)
42. DJ Peacock ML Banquerigo E Brahn 1992 Angiogenesis inhibition suppresses collagen arthritis J Exp Med 175 1135 1138 1372645 1:CAS:528:DyaK38Xhs1Gqtrc%3D
43. DJ Peacock ML Banquerigo E Brahn 1995 A novel angiogenesis inhibitor suppresses rat adjuvant arthritis Cell Immunol 160 178 184 7536634 1:CAS:528:DyaK2MXjs1Kgur0%3D
44. J Bainbridge L Madden D Essex M Binks R Malhotra EM Paleolog 2007 Methionine aminopeptidase-2 blockade reduces chronic collagen-induced arthritis: potential role for angiogenesis inhibition Arthritis Res Ther 9 R127 18072970
45. E Brahn ML Banquerigo JK Lee EJ Park WE Fogler SM Plum 2008 An angiogenesis inhibitor, 2-methoxyestradiol, involutes rat collagen-induced arthritis and suppresses gene expression of synovial vascular endothelial growth factor and basic fibroblast growth factor J Rheumatol 35 2119 2128 18792999 1:CAS:528:DC%2BD1cXhsVKmtrjK
46. H Sone Y Kawakami M Sakauchi Y Nakamura A Takahashi H Shimano Y Okuda T Segawa H Suzuki N Yamada 2001 Neutralization of vascular endothelial growth factor prevents collagen-induced arthritis and ameliorates established disease in mice Biochem Biophys Res Commun 281 562 568 11181084 1:CAS:528: DC%2BD3MXht1ahsr8%3D (Pubitemid 32928191)
47. J Miotla R Maciewicz J Kendrew M Feldmann E Paleolog 2000 Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis Lab Invest 80 1195 1205 10950110 1:CAS:528:DC%2BD3cXmtFOgsrs%3D (Pubitemid 30637059)
48. AO Afuwape M Feldmann EM Paleolog 2003 Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritis Gene Ther 10 1950 1960 14528319 1:CAS:528:DC%2BD3sXnsl2rsbw%3D (Pubitemid 37337071)
49. M de Bandt MH Ben Mahdi V Ollivier M Grossin M Dupuis M Gaudry P Bohlen KE Lipson A Rice Y Wu MA Gougerot-Pocidalo C Pasquier 2003 Blockade of vascular endothelial growth factor receptor I (VEGF-RI), but not VEGF-RII, suppresses joint destruction in the K/BxN model of rheumatoid arthritis J Immunol 171 4853 4859 14568965 (Pubitemid 37310607)
50. A Luttun M Tjwa L Moons Y Wu A Angelillo-Scherrer F Liao JA Nagy A Hooper J Priller B De Klerck V Compernolle E Daci P Bohlen M Dewerchin JM Herbert R Fava P Matthys G Carmeliet D Collen HF Dvorak DJ Hicklin P Carmeliet 2002 Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 Nat Med 8 831 840 12091877 1:CAS:528:DC%2BD38Xls12msLs%3D
51. J Folkman 1971 Tumor angiogenesis: therapeutic implications N Engl J Med 285 1182 1186 4938153 1:STN:280:DyaE38%2FgvVCqsQ%3D%3D
52. F Kabbinavar HI Hurwitz L Fehrenbacher NJ Meropol WF Novotny G Lieberman S Griffing E Bergsland 2003 Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 21 60 65 12506171 1:CAS:528: DC%2BD2cXpsVWru7Y%3D
53. H Hurwitz L Fehrenbacher W Novotny T Cartwright J Hainsworth W Heim J Berlin A Baron S Griffing E Holmgren N Ferrara G Fyfe B Rogers R Ross F Kabbinavar 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335 2342 15175435 1:CAS:528:DC%2BD2cXks1Gjt74%3D (Pubitemid 38702844)
54. BJ Giantonio PJ Catalano NJ Meropol PJ O'Dwyer EP Mitchell SR Alberts MA Schwartz AB Benson 2007 Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 1539 1544 17442997 1:CAS:528:DC%2BD2sXlsVyntbc%3D (Pubitemid 46733080)
55. FF Kabbinavar J Schulz M McCleod T Patel JT Hamm JR Hecht R Mass B Perrou B Nelson WF Novotny 2005 Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial J Clin Oncol Official J Am Soc Clin Oncol 23 3697 3705 1:CAS:528:DC%2BD2MXlslWntr0%3D
56. JM Llovet S Ricci V Mazzaferro P Hilgard E Gane J-F Blanc AC de Oliveira A Santoro J-L Raoul A Forner M Schwartz C Porta S Zeuzem L Bolondi TF Greten PR Galle J-F Seitz I Borbath D Häussinger T Giannaris M Shan M Moscovici D Voliotis J Bruix 2008 Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378 390 18650514 1:CAS:528:DC%2BD1cXovFWjsL8%3D
57. KD Miller LI Chap FA Holmes MA Cobleigh PK Marcom L Fehrenbacher M Dickler BA Overmoyer JD Reimann AP Sing V Langmuir HS Rugo 2005 Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer J Clin Oncol Official J Am Soc Clin Oncol 23 792 799 1:CAS:528:DC%2BD2MXitVKitrk%3D (Pubitemid 46224178)
58. A Sandler R Gray MC Perry J Brahmer JH Schiller A Dowlati R Lilenbaum DH Johnson 2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2542 2550 17167137 1:CAS:528:DC%2BD28XhtlWqsbzI (Pubitemid 44917502)
59. B Escudier T Eisen WM Stadler C Szczylik S Oudard M Siebels S Negrier C Chevreau E Solska AA Desai F Rolland T Demkow TE Hutson M Gore S Freeman B Schwartz M Shan R Simantov RM Bukowski 2007 Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 125 134 17215530 1:CAS:528: DC%2BD2sXksVKitg%3D%3D (Pubitemid 46089673)
60. HX Chen JN Cleck 2009 Adverse effects of anticancer agents that target the VEGF pathway Nature Rev Clin Oncol 6 465 477 1:CAS:528:DC%2BD1MXpsFyhsbY%3D
61. S Wu C Kim L Baer X Zhu 2010 Bevacizumab increases risk for severe proteinuria in cancer patients J Am Soc Nephrol 21 1381 1389 20538785 1:CAS:528:DC%2BC3cXhtVyku73K
62. BA George XJ Zhou R Toto 2007 Nephrotic syndrome after bevacizumab: case report and literature review Am J Kidney Dis 49 e23 e29 17261417
63. FA Scappaticci JR Skillings SN Holden H-P Gerber K Miller F Kabbinavar E Bergsland J Ngai E Holmgren J Wang H Hurwitz 2007 Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab J Natl Cancer Inst 99 1232 1239 17686822 (Pubitemid 47299901)
64. Schutz FA, Je Y, Azzi GR, Nguyen PL, Choueiri TK (2010) Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol. doi: 10.1093/annonc/mdq587
65. SR Nalluri D Chu R Keresztes X Zhu S Wu 2008 Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients J Am Med Assoc 300 2277 2285 1:CAS:528:DC%2BD1cXhtlyrt77O
66. S Hapani D Chu S Wu 2009 Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis Lancet Oncol 10 559 568 19482548 1:CAS:528:DC%2BD1MXms12jtbk%3D
67. HS Hochster LL Hart RK Ramanathan BH Childs JD Hainsworth AL Cohn L Wong L Fehrenbacher Y Abubakr MW Saif L Schwartzberg E Hedrick 2008 Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study J Clin Oncol Official J Am Soc Clin Oncol 26 3523 3529 1:CAS:528:DC%2BD1cXpvVWmtLs%3D
68. CJ Allegra G Yothers MJ O'Connell S Sharif LH Colangelo SH Lopa NJ Petrelli RM Goldberg JN Atkins TE Seay L Fehrenbacher S O'Reilly L Chu CA Azar N Wolmark 2009 Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with Stage II or III colon cancer J Clin Oncol 27 3385 3390 19414665 1:CAS:528:DC%2BD1MXpvFejtL4%3D
69. DA August D Serrano E Poplin 2008 "Spontaneous", delayed colon and rectal anastomotic complications associated with bevacizumab therapy J Surg Oncol 97 180 185 18095268 1:CAS:528:DC%2BD1cXislGisLw%3D (Pubitemid 351169051)
70. T Bège B Lelong F Viret O Turrini J Guiramand D Topart L Moureau-Zabotto M Giovannini A Gonçalves JR Delpero 2009 Bevacizumab-related surgical site complication despite primary tumor resection in colorectal cancer patients Ann Surg Oncol 16 856 860 19156464
71. FDA (2010) FDA begins process to remove breast cancer indication from Avastin label. United States Food and Drug Administration; [updated 2010; cited 2010 16th December]. Available from http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm237172.htm
72. NICE (2010) Colorectal cancer (metastatic)-bevacizumab. National Institute for Health and Clinical Excellence; [updated 2010; cited]. Available from http://www.nice.org.uk/guidance/index.jsp?action=byID&o=13291
73. H Sano R Forough JA Maier JP Case A Jackson K Engleka T Maciag RL Wilder 1990 Detection of high levels of heparin binding growth factor-1 (acidic fibroblast growth factor) in inflammatory arthritic joints J Cell Biol 110 1417 1426 1691192 1:CAS:528:DyaK3cXitFClu7g%3D
74. H Sano K Engleka P Mathern T Hla LJ Crofford EF Remmers CL Jelsema E Goldmuntz T Maciag RL Wilder 1993 Coexpression of phosphotyrosine-containing proteins, platelet-derived growth factor-B, and fibroblast growth factor-1 in situ in synovial tissues of patients with rheumatoid arthritis and Lewis rats with adjuvant or streptococcal cell wall arthritis J Clin Invest 91 553 565 7679410 1:CAS:528:DyaK3sXisFals70%3D (Pubitemid 23064141)
75. EF Remmers H Sano R Lafyatis JP Case GK Kumkumian T Hla T Maciag RL Wilder 1991 Production of platelet derived growth factor B chain (PDGF-B/c-sis) mRNA and immunoreactive PDGF B-like polypeptide by rheumatoid synovium: coexpression with heparin binding acidic fibroblast growth factor-1 J Rheumatol 18 7 13 1708827 1:CAS:528:DyaK3MXktVKnsr4%3D
76. AE Koch MM Halloran S Hosaka MR Shah CJ Haskell SK Baker RJ Panos GK Haines GL Bennett RM Pope N Ferrara 1996 Hepatocyte growth factor. A cytokine mediating endothelial migration in inflammatory arthritis Arthritis Rheum 39 1566 1575 8814069 1:STN:280:DyaK28vgvFSrtA%3D%3D (Pubitemid 26314991)
77. BB Scott PF Zaratin A Colombo MJ Hansbury JD Winkler JR Jackson 2002 Constitutive expression of angiopoietin-1 and -2 and modulation of their expression by inflammatory cytokines in rheumatoid arthritis synovial fibroblasts J Rheumatol 29 230 239 11838839 1:CAS:528:DC%2BD38XhsF2iurk%3D (Pubitemid 34118766)
78. EM Gravallese AR Pettit R Lee R Madore C Manning A Tsay J Gaspar MB Goldring SR Goldring P Oettgen 2003 Angiopoietin-1 is expressed in the synovium of patients with rheumatoid arthritis and is induced by tumour necrosis factor alpha Ann Rheum Dis 62 100 107 12525377 1:CAS:528:DC%2BD3sXhtlSiu7s%3D (Pubitemid 36135383)
79. LM DeBusk Y Chen T Nishishita J Chen JW Thomas PC Lin 2003 Tie2 receptor tyrosine kinase, a major mediator of tumor necrosis factor alpha-induced angiogenesis in rheumatoid arthritis Arthritis Rheum 48 2461 2471 13130465 1:CAS:528:DC%2BD3sXot1Wjsbc%3D (Pubitemid 37129423)
80. S Shahrara MV Volin MA Connors GK Haines AE Koch 2002 Differential expression of the angiogenic Tie receptor family in arthritic and normal synovial tissue Arthritis Res 4 201 208 12010571 1:CAS:528:DC%2BD38XjsVKjtL4%3D (Pubitemid 34460760)
81. T Uchida M Nakashima Y Hirota Y Miyazaki T Tsukazaki H Shindo 2000 Immunohistochemical localisation of protein tyrosine kinase receptors Tie-1 and Tie-2 in synovial tissue of rheumatoid arthritis: correlation with angiogenesis and synovial proliferation Ann Rheum Dis 59 607 614 10913057 1:CAS:528:DC%2BD3cXmtVCitbs%3D (Pubitemid 30617086)
82. Y Chen E Donnelly H Kobayashi LM Debusk PC Lin 2005 Gene therapy targeting the Tie2 function ameliorates collagen-induced arthritis and protects against bone destruction Arthritis Rheum 52 1585 1594 15880817 1:CAS:528:DC%2BD2MXkvFCis74%3D (Pubitemid 40663951)
83. P Jin J Zhang PF Sumariwalla I Ni B Jorgensen D Crawford S Phillips M Feldmann HM Shepard EM Paleolog 2008 Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis Arthritis Res Ther 10 R73 18593464
84. NM Malik P Jin Y Raatz PF Sumariwalla S Kiriakidis M Shepard M Feldmann EM Paleolog 2010 Regulation of the Angiopoietin-Tie ligand-receptor system with a novel splice variant of Tie1 reduces the severity of murine arthritis Rheumatology 49 1828 1839 20547659 1:CAS:528:DC%2BC3cXhtFGhtLfO
85. Y Yarden 2001 The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities Eur J Cancer 37 Suppl 4 S3 S8 11597398 1:CAS:528:DC%2BD3MXntlOku78%3D
86. Y Yarden MX Sliwkowski 2001 Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2 127 137 11252954 1:CAS:528:DC%2BD3MXivVWnt7k%3D (Pubitemid 33674041)
87. Z Huang C Brdlik P Jin HM Shepard 2009 A pan-HER approach for cancer therapy: background, current status and future development Expert Opin Biol Ther 9 97 110 19063696 1:CAS:528:DC%2BD1cXhsVKrs7vJ
88. M Scaltriti J Baselga 2006 The epidermal growth factor receptor pathway: a model for targeted therapy Clin Cancer Res Official J Am Assoc Cancer Res 12 5268 5272 1:CAS:528:DC%2BD28XpvFShs74%3D (Pubitemid 44497237)
89. JP Spano C Lagorce D Atlan G Milano J Domont R Benamouzig A Attar J Benichou A Martin JF Morere M Raphael F Penault-Llorca JL Breau R Fagard D Khayat P Wind 2005 Impact of EGFR expression on colorectal cancer patient prognosis and survival Ann Oncol 16 102 108 15598946 (Pubitemid 40124486)
90. I Zlobec T Vuong S Hayashi D Haegert L Tornillo L Terracciano A Lugli J Jass 2007 A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy Br J Cancer 96 793 800 17311026 1:CAS:528:DC%2BD2sXisVGisrc%3D (Pubitemid 46376624)
91. S Shiozawa K Shiozawa Y Tanaka I Morimoto M Uchihashi T Fujita K Hirohata Y Hirata S Imura 1989 Human epidermal growth factor for the stratification of synovial lining layer and neovascularisation in rheumatoid arthritis Ann Rheum Dis 48 820 828 2479344 1:STN:280:DyaK3c%2FlsFequw%3D%3D (Pubitemid 19258535)
92. S Di Cosimo J Baselga 2008 Targeted therapies in breast cancer: where are we now? Eur J Cancer 44 2781 2790 19013786 1:CAS:528:DC%2BD1cXhsVKltr%2FK
93. JB Johnston S Navaratnam MW Pitz JM Maniate E Wiechec H Baust J Gingerich GP Skliris LC Murphy M Los 2006 Targeting the EGFR pathway for cancer therapy Curr Med Chem 13 3483 3492 17168718 1:CAS:528:DC%2BD28Xht1aks7fF (Pubitemid 44873742)
94. AL Hallbeck TM Walz K Briheim A Wasteson 2005 TGF-alpha and ErbB2 production in synovial joint tissue: increased expression in arthritic joints Scand J Rheumatol 34 204 211 16134726 1:CAS:528:DC%2BD2MXnsVCgsLs%3D (Pubitemid 40978641)
95. K Satoh S Kikuchi M Sekimata Y Kabuyama MK Homma Y Homma 2001 Involvement of ErbB-2 in rheumatoid synovial cell growth Arthritis Rheum 44 260 265 11229455 1:CAS:528:DC%2BD3MXitlCgtLY%3D (Pubitemid 32207018)
96. AB Schreiber ME Winkler R Derynck 1986 Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor Science 232 1250 1253 2422759 1:CAS:528:DyaL28XktF2ns74%3D (Pubitemid 16066000)
97. S Yamane S Ishida Y Hanamoto K Kumagai R Masuda K Tanaka N Shiobara N Yamane T Mori T Juji N Fukui T Itoh T Ochi R Suzuki 2008 Proinflammatory role of amphiregulin, an epidermal growth factor family member whose expression is augmented in rheumatoid arthritis patients J Inflamm (Lond) 5 5
98. PF Sumariwalla P Jin J Zhang I Ni D Crawford HM Shepard EM Paleolog M Feldmann 2008 Antagonism of the human epidermal growth factor receptor family controls disease severity in murine collagen-induced arthritis Arthritis Rheum 58 3071 3080 18821697 1:CAS:528:DC%2BD1cXht12rurzP
99. GL Semenza 2009 Regulation of oxygen homeostasis by hypoxia-inducible factor 1 Physiology (Bethesda) 24 97 106 1:CAS:528:DC%2BD1MXltFenurk%3D
100. GL Wang BH Jiang EA Rue GL Semenza 1995 Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension Proc Natl Acad Sci USA 92 5510 5514 7539918 1:CAS:528:DyaK2MXmtFOgs7k%3D
101. PH Maxwell MS Wiesener GW Chang SC Clifford EC Vaux ME Cockman CC Wykoff CW Pugh ER Maher PJ Ratcliffe 1999 The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis Nature 399 271 275 10353251 1:CAS:528:DyaK1MXjsFyqt74%3D (Pubitemid 29246458)
102. B Sivakumar MA Akhavani CP Winlove PC Taylor EM Paleolog N Kang 2008 Synovial hypoxia as a cause of tendon rupture in rheumatoid arthritis J Hand Surg [Am] 33 49 58 (Pubitemid 351193088)
103. K Lund-Olesen 1970 Oxygen tension in synovial fluids Arthritis Rheum 13 769 776 5495389 1:STN:280:DyaE3M%2Fos1equg%3D%3D
104. PS Treuhaft D McCarty 1971 Synovial fluid pH, lactate, oxygen and carbon dioxide partial pressure in various joint diseases Arthritis Rheum 14 475 484 5564921 1:STN:280:DyaE3M3nsFSmtw%3D%3D
105. DR Blake P Merry J Unsworth BL Kidd JM Outhwaite R Ballard CJ Morris L Gray J Lunec 1989 Hypoxic-reperfusion injury in the inflamed human joint Lancet 1 289 293 2563454 1:STN:280:DyaL1M7is1Kmug%3D%3D (Pubitemid 19049402)
106. D Naughton M Whelan EC Smith R Williams DR Blake M Grootveld 1993 An investigation of the abnormal metabolic status of synovial fluid from patients with rheumatoid arthritis by high field proton nuclear magnetic resonance spectroscopy FEBS Lett 317 135 138 8381364 1:CAS:528:DyaK3sXhsVGjt7g%3D (Pubitemid 23043956)
107. YA Lee JY Kim SJ Hong SH Lee MC Yoo KS Kim HI Yang 2007 Synovial proliferation differentially affects hypoxia in the joint cavities of rheumatoid arthritis and osteoarthritis patients Clin Rheumatol 26 2023 2029 17393234 (Pubitemid 350120338)
108. DP Naughton 2003 Hypoxia-induced upregulation of the glycolytic enzyme glucose-6-phosphate isomerase perpetuates rheumatoid arthritis Med Hypotheses 60 332 334 12581606 1:CAS:528:DC%2BD3sXisFansL8%3D (Pubitemid 36237958)
109. CA Hitchon HS El-Gabalawy T Bezabeh 2009 Characterization of synovial tissue from arthritis patients: a proton magnetic resonance spectroscopic investigation Rheumatol Int 29 1205 1211 19184029
110. M Biniecka A Kennedy U Fearon CT Ng DJ Veale JN O'Sullivan 2010 Oxidative damage in synovial tissue is associated with in vivo hypoxic status in the arthritic joint Ann Rheum Dis 69 1172 1178 19706618
111. CT Ng M Biniecka A Kennedy J McCormick O Fitzgerald B Bresnihan D Buggy CT Taylor J O'Sullivan U Fearon DJ Veale 2010 Synovial tissue hypoxia and inflammation in vivo Ann Rheum Dis 69 1389 1395 20439288 1:CAS:528: DC%2BC3cXhtVSlur7E
112. AI Richman EY Su G Ho Jr 1981 Reciprocal relationship of synovial fluid volume and oxygen tension Arthritis Rheum 24 701 705 6786298 1:STN:280:DyaL3M3gslektw%3D%3D (Pubitemid 11099286)
113. C Hitchon K Wong G Ma J Reed D Lyttle H El-Gabalawy 2002 Hypoxia-induced production of stromal cell-derived factor 1 (CXCL12) and vascular endothelial growth factor by synovial fibroblasts Arthritis Rheum 46 2587 2597 12384916 1:CAS:528:DC%2BD38XovVWitr4%3D (Pubitemid 36118921)
114. AP Hollander KP Corke AJ Freemont CE Lewis 2001 Expression of hypoxia-inducible factor 1alpha by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint Arthritis Rheum 44 1540 1544 11465705 1:CAS:528:DC%2BD38Xkt1am (Pubitemid 32642216)
115. A Giatromanolaki E Sivridis E Maltezos N Athanassou D Papazoglou KC Gatter AL Harris MI Koukourakis 2003 Upregulated hypoxia inducible factor-1alpha and -2alpha pathway in rheumatoid arthritis and osteoarthritis Arthritis Res Ther 5 R193 R201 12823854 1:CAS:528:DC%2BD3sXjvVGhsbs%3D
116. J Westra G Molema CG Kallenberg 2010 Hypoxia-inducible factor-1 as regulator of angiogenesis in rheumatoid arthritis-therapeutic implications Curr Med Chem 17 254 263 20214567 1:CAS:528:DC%2BC3cXhsVSlsLw%3D
117. CL Peters CJ Morris PI Mapp DR Blake CE Lewis VR Winrow 2004 The transcription factors hypoxia-inducible factor 1alpha and Ets-1 colocalize in the hypoxic synovium of inflamed joints in adjuvant-induced arthritis Arthritis Rheum 50 291 296 14730627 1:CAS:528:DC%2BD2cXht1Kqsrg%3D (Pubitemid 38084314)
118. HL Kim YS Cho H Choi YS Chun ZH Lee JW Park 2009 Hypoxia-inducible factor 1alpha is deregulated by the serum of rats with adjuvant-induced arthritis Biochem Biophys Res Commun 378 123 128 19013431 1:CAS:528:DC%2BD1cXhsVOis7fP
119. MA Akhavani L Madden I Buysschaert B Sivakumar N Kang EM Paleolog 2009 Hypoxia upregulates angiogenesis and synovial cell migration in rheumatoid arthritis Arthritis Res Ther 11 R64 19426483
120. JK Ahn EM Koh HS Cha YS Lee J Kim EK Bae KS Ahn 2008 Role of hypoxia-inducible factor-1alpha in hypoxia-induced expressions of IL-8, MMP-1 and MMP-3 in rheumatoid fibroblast-like synoviocytes Rheumatology (Oxford) 47 834 839 1:CAS:528:DC%2BD1cXmtlent7s%3D (Pubitemid 351796369)
121. K Matsumoto S Imagawa N Obara N Suzuki S Takahashi T Nagasawa M Yamamoto 2006 2-Oxoglutarate downregulates expression of vascular endothelial growth factor and erythropoietin through decreasing hypoxia-inducible factor-1alpha and inhibits angiogenesis J Cell Physiol 209 333 340 16883594 1:CAS:528: DC%2BD28XhtVClu7nF (Pubitemid 44484623)
122. K Matsumoto N Obara M Ema M Horie A Naka S Takahashi S Imagawa 2009
123. EJ Yeo YS Chun YS Cho J Kim JC Lee MS Kim JW Park 2003 YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1 J Natl Cancer Inst 95 516 525 12671019 1:CAS:528:DC%2BD3sXislyjs74%3D (Pubitemid 36511622)
124. H Manabe Y Nasu T Komiyama T Furumatsu A Kitamura S Miyazawa Y Ninomiya T Ozaki H Asahara K Nishida 2008 Inhibition of histone deacetylase down-regulates the expression of hypoxia-induced vascular endothelial growth factor by rheumatoid synovial fibroblasts Inflamm Res 57 4 10 18209959 1:CAS:528:DC%2BD1cXitFaisrc%3D
125. J Shankar PB Thippegowda SA Kanum 2009 Inhibition of HIF-1alpha activity by BP-1 ameliorates adjuvant induced arthritis in rats Biochem Biophys Res Commun 387 223 228 19664474 1:CAS:528:DC%2BD1MXps1Chtr0%3D
126. EM Paleolog JM Miotla 1998 Angiogenesis in arthritis: role in disease pathogenesis and as a potential therapeutic target Angiogenesis 2 295 307 14517450 1:STN:280:DC%2BD3svlsFajsg%3D%3D (Pubitemid 128514257)
127. TL Khong H Larsen Y Raatz E Paleolog 2007 Angiogenesis as a therapeutic target in arthritis: learning the lessons of the colorectal cancer experience Angiogenesis 10 243 258 17805984 1:CAS:528:DC%2BD2sXht1ClurvP (Pubitemid 350045884)
128. N Ferrara K Carver-Moore H Chen M Dowd L Lu KS O'Shea L Powell-Braxton KJ Hillan MW Moore 1996 Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene Nature 380 439 442 8602242 1:CAS:528: DyaK28XitVKqtLk%3D (Pubitemid 26102720)
129. MA Gonzalez-Gay C Gonzalez-Juanatey J Martin 2005 Rheumatoid arthritis: a disease associated with accelerated atherogenesis Semin Arthritis Rheum 35 8 17 16084219 (Pubitemid 41111466)
130. MJ Kaplan 2006 Cardiovascular disease in rheumatoid arthritis Curr Opin Rheumatol 18 289 297 16582694 1:CAS:528:DC%2BD28XjtVKqsbY%3D (Pubitemid 43740382)
131. S Van Doornum C Brand B King V Sundararajan 2006 Increased case fatality rates following a first acute cardiovascular event in patients with rheumatoid arthritis Arthritis Rheum 54 2061 2068 16802340 (Pubitemid 44051061)
132. S Sihvonen M Korpela P Laippala J Mustonen A Pasternack 2004 Death rates and causes of death in patients with rheumatoid arthritis: a population-based study Scand J Rheumatol 33 221 227 15370716 1:STN:280:DC%2BD2crjslWitA%3D%3D (Pubitemid 39180164)
133. Z Nadareishvili K Michaud JM Hallenbeck F Wolfe 2008 Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study Arthritis Rheum 59 1090 1096 18668583
134. DH Solomon EW Karlson EB Rimm CC Cannuscio LA Mandl JE Manson MJ Stampfer GC Curhan 2003 Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis Circulation 107 1303 1307 12628952 (Pubitemid 36314415)
135. HM Kremers CS Crowson TM Therneau VL Roger SE Gabriel 2008 High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study Arthritis Rheum 58 2268 2274 18668561
136. DH Solomon NJ Goodson JN Katz ME Weinblatt J Avorn S Setoguchi C Canning S Schneeweiss 2006 Patterns of cardiovascular risk in rheumatoid arthritis Ann Rheum Dis 65 1608 1612 16793844 1:STN:280:DC%2BD28jgvFKjtA%3D%3D (Pubitemid 44799673)
137. P Soltesz H Der G Kerekes P Szodoray G Szucs K Danko Y Shoenfeld G Szegedi Z Szekanecz 2009 A comparative study of arterial stiffness, flow-mediated vasodilation of the brachial artery, and the thickness of the carotid artery intima-media in patients with systemic autoimmune diseases Clin Rheumatol 28 655 662 19224126
138. C Warnecke A Weidemann M Volke R Schietke X Wu KX Knaup T Hackenbeck W Bernhardt C Willam KU Eckardt MS Wiesener 2008 The specific contribution of hypoxia-inducible factor-2alpha to hypoxic gene expression in vitro is limited and modulated by cell type-specific and exogenous factors Exp Cell Res 314 2016 2027 18420194 1:CAS:528:DC%2BD1cXnt1Omurs%3D
139. VA Carroll M Ashcroft 2006 Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway Cancer Res 66 6264 6270 16778202 1:CAS:528:DC%2BD28XlvVSktL0%3D
140. HM Sowter RR Raval JW Moore PJ Ratcliffe AL Harris 2003 Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia Cancer Res 63 6130 6134 14559790 1:CAS:528:DC%2BD3sXotV2jtLg%3D (Pubitemid 37255150)
141. RR Raval KW Lau MG Tran HM Sowter SJ Mandriota JL Li CW Pugh PH Maxwell AL Harris PJ Ratcliffe 2005 Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma Mol Cell Biol 25 5675 5686 15964822 1:CAS:528:DC%2BD2MXlslCjt7Y%3D (Pubitemid 40853601)
142. T Bongartz AJ Sutton MJ Sweeting I Buchan EL Matteson V Montori 2006 Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials JAMA 295 2275 2285 16705109 1:CAS:528:DC%2BD28Xksl2ktrk%3D (Pubitemid 43736578)
143. T Bongartz FC Warren D Mines EL Matteson KR Abrams AJ Sutton 2009 Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials Ann Rheum Dis 68 1177 1183 19019889 1:CAS:528: DC%2BD1MXovVCmsrc%3D
144. DE Furst 2008 The risk of infections with biologic therapies for rheumatoid arthritis Semin Arthritis Rheum 39 327 346 19117595
145. F Tubach D Salmon P Ravaud Y Allanore P Goupille M Breban B Pallot-Prades S Pouplin A Sacchi RM Chichemanian S Bretagne D Emilie M Lemann O Lorthololary X Mariette 2009 Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective french research axed on tolerance of biotherapies registry Arthritis Rheum 60 1884 1894 19565495 1:CAS:528: DC%2BD1MXptlKktLo%3D